Toutes les catégories
| Product Name | Description | Action |
|---|---|---|
| Amivantamab,Rybrevant,EGFR, cMet (MET),JNJ-61186372,anticorps bispécifiques à l'EGFR/c-MET,bispécifiques à l'IgG1 entièrement chez l'homme,immunothérapie oncologique /LCNS biologique,no CAS 2171511-58-1 | Trade Name : Rybrevant Target : EGFR, cMet (MET) Molecular Type : Bispecific Antibody Sales in 2025 (Millions of USD) : 179(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in ... |
|
| Le polotuzumab vedotin,Polivy,CD79B,RG7596,ADC,traitement ciblé CD79b,inhibiteur des microtubules,ADC d'oncologie / ADC de DLBCL / ADC de lymphome,infusion intraveineuse,no CAS 1313206-42-6 | Trade Name : Polivy Target : CD79B Molecular Type : ADC Sales in 2025 (Millions of USD) : 850(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Obinutuzumab, Gazyva, CD20, GA101, N ° CAS 949142-50-1, Anticorps monoclonaux anti-CD20 (type II), Anticorps IgG1 généré par la glycosynthèse humaine,Oncologie biologique / CLL biologique / Lymphome folliculaire biologique | Trade Name : Gazyva Target : CD20 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 784(First three quarters) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Ivonescimab, YIDAFANG® ((noms commerciaux approuvés pour une utilisation en Chine), AK112, PD-1/VEGF anticorps bispécifique, Oncologie immunothérapie / thérapie antiangiogénique, PD-1/VEGF anticorps bispécifique, CAS no.2428381-53-5 Je suis désolé. | Trade Name : YIDAFANG® (Trade names approved for use in China) Target : N/A Molecular Type : PD-1/VEGF Bispecific antibody Sales in 2025 (Millions of USD) : 28(In 2024) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this ... |
|
| Datopotamab deruxtecan-dlnk ,Datroway ,TROP-2 ,DS-1062 ,ADC ,Thérapie ciblée TROP2 ,Inhibiteur de la topoisomérase I ,ADC oncologique / ADC pour CBNPC / ADC pour cancer du sein ,N° CAS 2238831-60-0 | Trade Name : Datroway Target : TROP-2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 10(First Quarter) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Ténécteplase, métalyse, fibrine, TNK-tPA, enzyme thrombolytique / fibrinolytique, tPA de troisième génération, protéine recombinante, n° CAS 191588-94-0 | Trade Name : Metalyse Target : Fibrin Molecular Type : Recombinant Protein Sales in 2025 (Millions of USD) : 1780(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Tarlatamab, Imdelltra, DLL3 et CD3, AMG 757, Immunothérapie oncologique / SCLC biologique, Infusion par voie intraveineuse, cytotoxicité médiée par les cellules T, Engager bi-spécifique des cellules T, CAS n ° 2307488-83-9 | Trade Name : Imdelltra Target : DLL3&CD3 Molecular Type : Bispecific T-cell Engager Sales in 2025 (Millions of USD) : 215(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in ... |
|
| Serplulimab ,HANSIZHUANG ,PD-1 ,Hetronifly ,HLX10 ,inhibiteur de point de contrôle immunitaire anti-PD-1 ,anticorps monoclonal IgG4 humanisé ,anticorps monoclonal ,N° CAS.2231029-82-4 | Trade Name : HANSIZHUANG Target : PD-1 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 82(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with ... |
